In this presentation given at Ending Age-Related Diseases 2020, Dr. Sajad Zalzala of AgelessRx discusses PEARL, a human trial of rapamycin that uses the participation of ordinary people in order to get a large sample size without the expense of a traditional clinical trial. He discusses the use and effectiveness of rapamycin as an aging treatment in previous studies of both rodents and people. He discusses the objectives of PEARL and provides reasons why this groundbreaking trial will not only provide evidence for the effectiveness of rapamycin in human beings but provide a new framework for future trials, aiding human longevity as a whole.

HOW CAN YOU SUPPORT US?
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
LEAF / Lifespan.io is a 501(c)(3) nonprofit organization. Everything we've done thus far and everything we will do in the future is thanks to your support - please stand with us to fight the diseases of aging and increase healthy human lifespan.
► Support us with monthly donations by becoming a Lifespan Hero: [ Ссылка ]
► Make a one-time donation and learn about other ways to support us here: [ Ссылка ]
► Learn more, and help us #CrowdsourceTheCure: [ Ссылка ]
► Subscribe: [ Ссылка ]

JOIN US
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
Join us, and together, we can overcome diseases like Alzheimer's, heart disease, and cancer by addressing their shared source: the aging processes themselves.

#Research #Aging #Funding #LEAF #Biotech

свернуть